Kyle Moran sold $4.1M of WVE
Chief Financial Officer at Wave Life Sciences Ltd.. 260,036 shares at an average of $15.78, traded Dec 8, 2025, filed Dec 10, 2025.
Score components
- +22RoleCFO
- +25Trade size$4.1M at market
- +20Share of holdings soldSold 100% of holdings
- +15Cluster8 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m -31.6%, 3m -30.4%, 6m -72.0%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001193125-25-314736, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Dec 8, 2025 | MOption exercise Ordinary Shares10b5-1 | +60,000 | $2.83 | $170k | 149,218 | Dec 10, 2025 |
| Dec 8, 2025 | SOpen-market sale Ordinary Shares10b5-1 | -60,000 | $13.20 | $792k | 89,218 | Dec 10, 2025 |
| Dec 8, 2025 | MOption exercise Ordinary Shares10b5-1 | +100,000 | $3.14 | $314k | 189,218 | Dec 10, 2025 |
| Dec 8, 2025 | SOpen-market sale Ordinary Shares10b5-1 | -50,000 | $15.00 | $750k | 139,218 | Dec 10, 2025 |
| Dec 8, 2025 | SOpen-market sale Ordinary Shares10b5-1 | -50,000 | $13.20 | $660k | 89,218 | Dec 10, 2025 |
| Dec 8, 2025 | MOption exercise Ordinary Shares10b5-1 | +50,000 | $4.75 | $238k | 139,218 | Dec 10, 2025 |
| Dec 8, 2025 | SOpen-market sale Ordinary Shares10b5-1 | -50,000 | $18.00 | $900k | 89,218 | Dec 10, 2025 |
| Dec 9, 2025 | MOption exercise Ordinary Shares10b5-1 | +36,000 | $8.17 | $294k | 125,218 | Dec 10, 2025 |
| Dec 9, 2025 | SOpen-market sale Ordinary Shares10b5-1 | -36 | $20.25 | $729 | 89,218 | Dec 10, 2025 |
| Dec 9, 2025 | MOption exercise Ordinary Shares10b5-1 | +50,000 | $10.48 | $524k | 139,218 | Dec 10, 2025 |
| Dec 9, 2025 | SOpen-market sale Ordinary Shares10b5-1 | -50,000 | $20.03 | $1.0M | 90,365 | Dec 10, 2025 |
| Dec 8, 2025 | AGrant or award Share Option (right to buy)derivative10b5-1 | -60,000 | $0.00 | $0 | 0 | Dec 10, 2025 |
| Dec 8, 2025 | AGrant or award Share Option (right to buy)derivative10b5-1 | -100,000 | $0.00 | $0 | 75,000 | Dec 10, 2025 |
| Dec 8, 2025 | AGrant or award Share Option (right to buy)derivative10b5-1 | -50,000 | $0.00 | $0 | 222,700 | Dec 10, 2025 |
| Dec 9, 2025 | AGrant or award Share Option (right to buy)derivative10b5-1 | -36,000 | $0.00 | $0 | 0 | Dec 10, 2025 |
| Dec 9, 2025 | AGrant or award Share Option (right to buy)derivative10b5-1 | -50,000 | $0.00 | $0 | 0 | Dec 10, 2025 |
Related signals
Other insiders at Wave Life Sciences Ltd. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 38Weak | Wave Life Sciences Ltd. | Adrian Rawcliffe director | $67k 12,700 shares | -100% | |
| 15Weak | Wave Life Sciences Ltd. | Ken Takanashi director | $23k 3,864 shares | -16% | |
| 10Weak | Wave Life Sciences Ltd. | Aik Na Tan director | $2,596 432 shares | -2% | |
| 6Weak | Wave Life Sciences Ltd. | Heidi L Wagner director | $42k 7,000 shares | -13% | |
| 49Moderate | WVEbuy Wave Life Sciences Ltd. | Ra Capital Management, L.p. director, owner | $55M 8,772,496 shares | +48% | |
| 8Weak | Wave Life Sciences Ltd. | Chris Francis See Remarks | $500k 33,194 shares | -42% | |
| 51Moderate | Wave Life Sciences Ltd. | Paul Bolno President and CEO | $141k 10,480 shares | -4% | |
| 35Weak | Wave Life Sciences Ltd. | Chris Francis See Remarks | $25k 1,883 shares | -3% | |
| 44Moderate | Wave Life Sciences Ltd. | Kyle Moran Chief Financial Officer | $48k 3,588 shares | -3% | |
| 36Weak | Wave Life Sciences Ltd. | Chandra Vargeese See Remarks | $43k 3,228 shares | -1% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.